next questions in the treatment and management of mpns
Published 3 years ago • 16 plays • Length 1:39Download video MP4
Download video MP3
Similar videos
-
1:51
checkpoint inhibition in the treatment of mpns
-
3:33
the importance of improving diagnosis in mpns and tailoring treatment approaches
-
2:06
an insight into the challenges and management of myeloproliferative neoplasm-unclassifiable (mpn-u)
-
1:30
advancements in prognostication tools in mpns in recent years
-
1:01
recent and future changes in the landscape of aml: the addition of venetoclax and mrd eradication
-
1:39
is core pain the same as unmet need?
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
3:48
efficacy of momelotinib in thrombocytopenic patients with myelofibrosis from momentum
-
1:02
the changing standard of care in dlbcl
-
1:22
managing cytopenias following jak inhibitor treatment & achieving true disease modification in mf
-
2:25
a final update of enhance: reflecting on the negative read-out of the study
-
3:46
an update on the summit trial: bezuclastinib in non-advanced systemic mastocytosis
-
13:31
key highlights in mpns: novel agents, combinations, and the potential role of immunotherapy
-
2:26
the challenges associated with transfusion dependence in patients with mf
-
2:39
managing the potential cardiotoxicity associated with btkis: important considerations
-
1:09
how to manage mpn patients
-
3:13
therapies for patients who progress on jak inhibitors: imetelstat, navtemadlin, selinexor & tp-3654
-
1:46
how can patients be advised about working with medical conditions?
-
17:23
updates in cll: key clinical trials in the frontline and r/r setting, pre-clinical data and mrd
-
1:02
the challenge of treating bpdcn in a resource-limited setting